Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Theriva Biologics Inc (AMEX: TOVX) closed at $1.47 down -9.26% from its previous closing price of $1.62. In other words, the price has decreased by -$9.26 from its previous closing price. On the day, 0.12 million shares were traded. TOVX stock price reached its highest trading level at $1.6106 during the session, while it also had its lowest trading level at $1.4293.
Ratios:
For a deeper understanding of Theriva Biologics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.67 and its Current Ratio is at 2.67. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOVX now has a Market Capitalization of 4090201 and an Enterprise Value of -11579494.
Stock Price History:
The Beta on a monthly basis for TOVX is 1.24, which has changed by -0.86 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, TOVX has reached a high of $17.11, while it has fallen to a 52-week low of $1.14. The 50-Day Moving Average of the stock is 0.55%, while the 200-Day Moving Average is calculated to be -70.96%.
Shares Statistics:
For the past three months, TOVX has traded an average of 1.90M shares per day and 942540 over the past ten days. A total of 2.78M shares are outstanding, with a floating share count of 2.75M. Insiders hold about 1.04% of the company’s shares, while institutions hold 17.68% stake in the company. Shares short for TOVX as of 1730332800 were 90953 with a Short Ratio of 0.07, compared to 1727654400 on 96864. Therefore, it implies a Short% of Shares Outstanding of 90953 and a Short% of Float of 4.01.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Theriva Biologics Inc (TOVX).The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$23.75 and -$23.75 for the fiscal current year, implying an average EPS of -$23.75.
